Why AstraZeneca’s EMERALD-3 and SERENA-6 data could influence future standards of cancer care
Could AstraZeneca’s latest ASCO 2026 cancer data reshape future treatment sequencing in liver and breast oncology? Read the full analysis.
Pharma & Biotech
Pharma & Biotech
ENHERTU enters curative-intent breast cancer care as FDA widens AstraZeneca and Daiichi Sankyo label
ENHERTU is moving earlier in breast cancer care. The bigger question is whether efficacy gains can outweigh ADC safety scrutiny.
Pharma & Biotech
Why AstraZeneca’s TRUQAP ODAC vote could reshape PTEN-deficient prostate cancer treatment
TRUQAP has ODAC support, but toxicity and survival maturity still matter. AstraZeneca’s prostate cancer expansion now faces FDA’s final test.
Pharma & Biotech
What Innate Pharma’s Kempen conference participation reveals about its 2026 biotech strategy
Innate Pharma heads to Kempen as investors assess its oncology pipeline, partnering outlook, and next catalysts. Read the full analysis.
Pharma & Biotech
Amani Therapeutics bets $25m on expanding clozapine access in schizophrenia
Amani Therapeutics raises $25M to advance AM-01, a fixed-dose clozapine combination targeting neutropenia. Analysis of what changes — and what risks remain.
Pharma & Biotech
Avacta (AIM: AVCT) FAP-Exd data challenges Enhertu on tumor selectivity ahead of Phase 1 start
Avacta Therapeutics (AIM: AVCT) has published preclinical data showing that its FAP-targeted payload delivery platform, FAP-Exd (AVA6103), outperforms the marketed antibody drug conjugate trastuzumab deruxtecan across three pharmacokinetic measures, with a Phase 1 clinical trial expected to begin in the first quarter of 2026. What the AI-generated comparator actually enables The methodological choice here deserves
Pharma & Biotech
What AstraZeneca’s KALOS and LOGOS data reveal about triple inhaler therapy in asthma
AstraZeneca’s KALOS and LOGOS trials highlight triple inhaler therapy gains in asthma. Explore what this means for guidelines and payers.
Pharma & Biotech
Is ENHERTU plus pertuzumab on track to redefine first-line treatment in HER2-positive metastatic breast cancer?
EMA begins review of ENHERTU plus pertuzumab for first-line HER2-positive metastatic breast cancer. Find out what this means for frontline therapy options.
Pharma & Biotech
What AstraZeneca’s C-CAR031 deal reveals about the future of CAR-T in liver cancer
AstraZeneca takes full control of a GPC3 CAR-T therapy for liver cancer. Find out what this deal changes and what risks still loom.
Pharma & Biotech
Can Lynx Analytics’ Lumen framework reshape AI-driven decision-making in life sciences?
Lynx Analytics has introduced Lumen, a dedicated agentic artificial intelligence framework designed to support complex decision-making across life sciences workflows. The launch was anchored by a real-world deployment at AstraZeneca, where a custom-built application called IlluminAI is now embedded in the oncology team’s brand planning process across international markets. The framework is positioned as a